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Acyl-CoAsHyperammonemia is a frequent ﬁnding in various organic acidemias. One possible mechanism involves the
inhibition of the enzyme N-acetylglutamate synthase (NAGS), by short-chain acyl-CoAs which accumulate due
to defective catabolism of amino acids and/or fatty acids in the cell. The aim of this study was to investigate the
effect of various acyl-CoAs on the activity of NAGS in conjunction with the formation of glutamate esters. NAGS
activity was measured in vitro using a sensitive enzyme assay with ultraperformance liquid chromatography–
tandem mass spectrometry (UPLC–MS/MS) product analysis. Propionyl-CoA and butyryl-CoA proved to be the
most powerful inhibitors of N-acetylglutamate (NAG) formation. Branched-chain amino acid related CoAs
(isovaleryl-CoA, 3-methylcrotonyl-CoA, isobutyryl-CoA) showed less pronounced inhibition of NAGS whereas
the dicarboxylic short-chain acyl-CoAs (methylmalonyl-CoA, succinyl-CoA, glutaryl-CoA) had the least inhibitory
effect. Subsequentwork showed that themost powerful inhibitors also proved to be the best substrates in the for-
mation of N-acylglutamates. Furthermore, we identiﬁed N-isovalerylglutamate, N-3-methylcrotonylglutamate
and N-isobutyrylglutamate (the latter two in trace amounts), in the urines of patients with different organic
acidemias. Collectively, these ﬁndings explain one of the contributing factors to secondary hyperammonemia,
which lead to the reduced in vivo ﬂux through the urea cycle in organic acidemias and result in the inadequate
elimination of ammonia.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The degradation of protein and subsequently amino acids is an
essential part of human metabolism. The catabolism of amino acids
and other nitrogen-containing molecules results in the production of
ammonia (NH3), which is converted into urea in the liver via the urea
cycle and excreted as such in the urine. The urea cycle consists of six
key enzymes, localized in different compartments within the cell, thus
requiring the obligatory participation of different mitochondrial
membrane transporters (SLC25A13 and SLC25A15). N-acetylglutamate
synthase (NAGS), carbamyl phosphate synthetase 1 (CPS) andornithineoA, coenzyme A; UPLC–MS/MS,
spectrometry; UCDs, urea cycle
entral nervous system; NAG,
ectrometry
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omics, North-West University
m, South Africa, 2520. Tel.:+27
ksen).
l rights reserved.transcarbamylase (OTC) are located in the mitochondrion whereas
argininosuccinate synthase (ASS), argininosuccinate lyase (ASL),
and arginase (ARG) reside in the cytosol [1]. The urea cycle plays a
key role in the control of ammonia levels which need to be kept as
low as possible in order to prevent the deleterious consequences of
hyperammonemia. Ammonia is especially toxic to the central nervous
system (CNS) since slight elevations in ammonia (>100 μM, normal:
b45 μM) may cause metabolic encephalopathy and irreversible CNS
damage [2].
CPS catalyzes the initial and rate limiting step of the urea cycle and
is vital for the regulation of the pathway. Its allosteric activator
N-acetylglutamate (NAG), is essential for the function of CPS in the
urea cycle [3]. NAGS (E.C. 2.3.1.1), originally identiﬁed in E. coli by
Vogel et al. [4] and later on described in humans by Bachmann et al.
[5], is responsible for the synthesis of N-acetylglutamate (NAG)
through the conjugation of acetyl-CoA and L-glutamate. The activity
of NAGS is stimulated by L-arginine, an allosteric activator [6]. Apart
from the short term regulation by NAG, urea cycle activity is also con-
trolled by several other mechanisms, including enzyme induction, the
concentration of intermediates and substrates, diet as well as hor-
monal changes. Although the precise regulation of ureagenesis is
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primary and secondary hyperammonemia [7,8].
Urea cycle enzyme and transporter defects (UCDs), including NAGS
deﬁciency, are a well deﬁned group of inherited metabolic disorders
characterized by episodes of mild to severe hyperammonemia [7,9].
Except for hyperammonemia caused by primary deﬁciencies in one of
the enzymes or transporters involved in the urea cycle, this pathophys-
iological condition is also observed in numerous other conditions. These
include liver disease, anatomical changes such as the portocaval shunt,
hyperinsulinism and hyperammonemia due to glutamate dehydroge-
nase hyperactivity, several organic acidemias, mitochondrial fatty acid
oxidation disorders and valproate toxicity [7,10–12]. Fig 1 illustrates
the localization of several CoA esters and part of the urea cycle within
the mitochondrion.
The elevation of blood ammonia encountered in the classical
organic acidemias, including isovaleric-, propionic- and methylmalonic
acidemia can be life-threatening [7]. Isolated cases of hyperammonemia
have been reported for some disorders e.g. 3-methylcrotonyl-CoA
carboxylase- (MCC), multiple acyl-CoA dehydrogenase- (MAD) and
succinyl-CoA ligase (associated with mutations in SUCLG1 gene) deﬁ-
ciencies [13–16]. Hyperammonemia in human short-chain acyl-CoA
dehydrogenase deﬁciency (SCADD) is virtually non-existent. Mice
with SCADD however have shown elevated blood ammonia levels
[17,18]. No cases associated with hyperammonemia have been docu-
mented for glutaryl-CoA dehydrogenase- (GA1), short/branched-chain
acyl-CoA dehydrogenase- (SBCAD) isobutyryl-CoA dehydrogenase-
(IBCAD), 3-ketothiolase- and multiple carboxylase deﬁciencies as wellCytoplasm
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Membrane transporters include solute carrier transporters, SLC25A13, SL25A15 and the oxod
the accumulation of short-branched-chain and short-chain CoA esters.as succinyl-CoA ligase deﬁciency due to SUCLA2 gene mutations.
[19–24]. These reports and previous ﬁndings indicate a clear variation
in the occurrence of hyperammonemia associated with short-chain-
and short-branched-chain organic acidemias [25]. The inhibition of
NAGS is one of the factors which may explain the presence of
hyperammonemia, among other. Additional information of these disor-
ders is summarized in Supplementary Table 1.
Since there is accumulation of a range of acyl-CoAs in the different
organic acidemias, we decided to study the effect of several acyl-CoAs
on the activity of NAGS as well as their behavior as substrates for the
enzyme, using an optimized UPLC–MS/MS assay. We argued that
these compounds may act as inhibitors and/or substitute substrates
for NAGS which would lead to the aberrant in vivo regulation of the
urea cycle and contribute (in addition to other factors) to episodes
of hyperammonemia.
2. Materials and Methods
All materials were supplied by Sigma-Aldrich (St. Louis, MO) unless
otherwise speciﬁed.
2.1. Preparation and puriﬁcation of human NAGS protein
The construction of the NAGS wild type plasmid, as well as the ex-
pression of human NAGS protein in E. coli was performed essentially
as described by Schmidt et al. [26] with minor modiﬁcations. The
coding sequence formature NAGS, without themitochondrial targetingValine
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Fig. 2. Inhibition of NAGS by isovaleryl-CoA and butyryl-CoA. The effect of (A)
isovaleryl-CoA (0-2.5 mM) and (B) butyryl-CoA (0-2.5 mM) on the activity of NAGS
was studied at different substrate concentrations (acetyl-CoA, 0-2.5 mM). Nonlinear
regression identiﬁed a mixed model inhibition as the best ﬁt mechanism.
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(generous gift from Dr. Johannes Häberle) using the forward primer
ATATCATATG AGCACCGCCTGGTCGCAGCCC and reverse primer
ATATGGATCCTCAGCTGCCTG GGTCAGAAG (NdeI and BamHI restriction
sites underlined). The PCR product was cloned into pGEM-T (Promega,
Madison, WI) resulting in pGEM-T-NAGS and was subsequently
sequenced. The NdeI/BamHI fragment from pGEM-T-NAGS was sub-
cloned in frame with the N-terminal 10xHis-tag of pET19b.
For protein expression thepET19b-NAGS constructwas transformed
into E.coli BL21 AI strain (Invitrogen, Carlsbad, CA). Cells were grown
from an overnight culture in Terriﬁc Broth medium containing glycerol
(8 g/L) and ampicilline (100 μg/mL) at 37 °C until an OD600 of 1-1.5
was reached. Thereafter the temperature was adjusted to 22 °C and
the mixture was allowed to cool for 1 hour to 22 °C. His-tagged NAGS
was expressed overnight at 22 °C by addition of L-arabinose (2 g/L)
and IPTG (0.2 mM). Cells were lysed in a buffer containing Tris
(25 mM, pH = 7.5) and NaCl (500 mM) by treatment with lysozyme
and sonication and the lysate was cleared by centrifugation (20,000 g,
15 minutes). To the supernatant imidazole (15 mM) and HisLink
Protein Puriﬁcation Resin (Promega, Madison, WI) was added. Protein
binding was allowed batchwise for 30 minutes at 4 °C. The resin
was poured into a column and washed with lysis buffer containing
imidazole (30 mM). NAGS was eluted from the column by increasing
the concentration of imidazole in the lysis buffer to 100 mM (Supple-
mentary Fig. 1). Glycerol (100 g/L) was added to the puriﬁed protein
and aliquots were snap-frozen in liquid nitrogen and stored at
-80 °C.
2.2. NAGS Enzyme Assay
The activity of NAGS, as expressed and puriﬁed from E.coli, was
measured essentially as described by Caldovic et al. with minor modiﬁ-
cations [27]. Brieﬂy, the reactionmixture contained 50 mMammonium
acetate buffer (ﬁnal pH = 8.5), 10 mM glutamate, 2.5 mM acetyl-CoA,
and 1 mM arginine in a 75 μl reaction volume. The reaction was started
by adding 0.05 μg puriﬁed enzyme (prepared in 0.1 mg/mL BSA/PBS
solution). The enzyme reactions were stopped with 175 μL acetonitrile,
after a 10 minute incubation period at 30 °C. All samples were placed
on ice and the internal standard, N-acetyl-L-glutamic-2,3,3,4,4-d5 acid
(CDN isotopes: Germany), was added. The precipitated protein was
removedby centrifugation (20,000 g, 5 minutes, 4 °C) and the superna-
tantwas dried under nitrogen at 40 °C. The productwas resuspended in
110 μL of 0.4% heptaﬂuorobutyric acid (HFBA) (pH 4) and 10 μL was
injected on the UPLC–MS/MS for monitoring of NAG and other
N-acylglutamates. The products were separated by UPLC and analysed
by multiple reaction monitoring (MRM) of selected mass pairs as
described by Aires et al. [12].
2.3. Kinetic investigation of puriﬁed NAGS and inhibitor selection
The puriﬁed enzyme was used in a series of kinetic experiments. A
complete kinetic investigation was performed with isovaleryl-CoA
and butyryl-CoA. The inhibitory effect of isovaleryl-CoA (0–2.5 mM)
and butyryl-CoA (0–2.5 mM) on the activity of NAGS was evaluated
using the NAGS assay described above. The characterization of the
NAGS activity with the two selected inhibitors was done by plotting
the measured reaction rates as a function of substrate and inhibitor
concentrations. Graph Pad Prism version 5 (GraphPad Software Inc.,
La Jolla, CA, USA) was used to perform nonlinear regression analysis of
the kinetic data and the Vmax, Km and Ki as well as the type of inhibition
were determined [28].
Additional short-chain acyl-CoAs, i.e. 3-methylcrotonyl-CoA,
methylmalonyl-CoA, glutaryl-CoA, succinyl-CoA, isobutyryl-CoA, and
propionyl-CoA were tested at a low (0.2 mM) and a high (2.5 mM)
concentration. The reaction conditions were the same as described
in Section 2.2.2.4. Chemical synthesis of N-acylglutamate conjugates
Various acylchlorides (propionylchloride, butyrylchloride, isobutyryl-
chloride, isovaleryl- chloride, succinylchloride, 3-methylcrotonylchloride
and glutarylchloride) were used in the synthesis of the glutamate con-
jugates in this study. Methylmalonylchloride was not commercially
available; therefore, we synthesized it by using amodiﬁedmethodology
originally described by Liebich and Först [29]. Two milliliters
thionylchloride (0.2 moles) was added to 0.6 moles of methylmalonic
acid. The mixture was incubated at 60 °C for 60 minutes. Acylchlorides
(1 mL), with an approximate concentration of 0.1 M, were added to
1 mL 2 M L-glutamate prepared in a 10 M NaOH solution. The reaction
was carried out on ice for 5 minutes. Thereafter, the solution was kept
at 60 °C for 2 hours to enhance further product formation. The solution
was subsequently acidiﬁed and an ethylacetate extraction was
performed. The organic phase was dried under a stream of nitrogen.
The dried product, which contained the N-acylglutamates, was stored
at -20 °C. Approximately 20 nmoles of the ﬁnal products were injected
on the UPLC–MS/MS in the MRM mode to check for the product and
precursor ions.
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short-chain organic acidemias
The presence of N-acylglutamates in urine of patients with different
organic acidemias was veriﬁed by GC–MS [30]. The synthesized
N-acylglutamate and urine samples were analysed under the same
GC–MS condition to establish the presence of metabolites. The mass
spectra of the synthetic glutamate conjugates were compared to organ-
ic acid proﬁles of patients and control subject (with no metabolic
disease) by using the Automated Mass Spectral Deconvolution and
Identiﬁcation System software (AMDIS, version 2.66 from the National
Institute for Standards and Technology).
3. Results
In order to study the effect of different acyl-CoAs on the activity of
the enzyme N-acetylglutamate synthase, we ﬁrst expressed human
His-tagged NAGS in E.coli and subsequently puriﬁed the expressed
protein using nickel chelate chromatography. To determine the enzyme
activity of the eluted protein, we developed a new enzyme assay (see
materials and methods) which involves the use of UPLC–MS/MS for
acquisition and stable isotope quantiﬁcation of the reaction product.
Using this method, the isolated protein showed abundant NAGS
activity.
3.1. Inhibition of NAGS activity by isovaleryl-CoA and butyryl-CoA
Enzyme analyses and kinetics were performed to study the inhib-
itory properties of isovaleryl-CoA and butyryl-CoA on NAGS. The
results are shown in Fig. 2. We determined the kinetic parameters
of puriﬁed NAGS which resulted in Vmax and Km values of 5.0 ±
0.11 μmol/min.mg protein and 0.3 ± 0.07 mM for acetyl-CoA, respec-
tively (values represent the mean and standard deviation of two sepa-
rate experiments). Isovaleryl-CoA has already been described as an
inhibitor of NAGS in rat liver mitochondria, but its inhibitory effect
has not been examined in detail with the puriﬁed NAGS enzyme [11].
The inhibition constants (Ki) were 1.9 mM for isovaleryl-CoA and
1.3 mM for butyryl-CoA, respectively. The alpha-value, which indicates
the probable mechanism of the mixed model inhibition (alpha = 1:% NAGS
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Fig. 3. The inhibitory effect of several acyl-CoAs on NAGS activity. The effect of different acyl-Co
of 2.5 mM. The activity in the absence of inhibitors was set at 100%.non-competitive; alpha b 1: uncompetitive; alpha > 1: competitive
inhibition), for isovaleryl-CoA and butyryl-CoA were 1.8 and 1.1, re-
spectively [31]. A comparison of the inhibition constants indicates that
butyryl-CoA is a stronger inhibitor of NAGS than isovaleryl-CoA.
3.2. The inhibitory effect of other short-chain acyl-CoAs on NAGS activity
The activity of NAGS was measured using standard reaction mix-
tures (as described in Section 2.2) with 2.5 mM acetyl-CoA in the
presence of different acyl-CoAs (0.2 mM and 2.5 mM) as indicated. The
results in Fig. 3 show that all acyl-CoAs including 3-methylcrotonyl-
CoA, methylmalonyl-CoA, glutaryl-CoA, succinyl-CoA, isobutyryl-CoA,
propionyl-CoA, butyryl-CoA, and isovaleryl-CoA have an inhibitory effect
on the activity of NAGS, although to different extent. Propionyl-CoA
appeared to be the strongest inhibitor followed by butyryl-CoA. The
branched-chain amino acid-related CoA esters had less of an inhibitory
effect and the dicarboxylic acyl-CoAs had the least effect on the activity
of NAGS.
3.3. Alternative N-acylglutamate conjugates formed by NAGS
Because of the inhibitory effect of various acyl-CoAs (0.2 mM)
on NAGS, we also examined the in vitro enzymatic formation of
N-acylglutamate esters by NAGS in the absence and presence of
0.2 mM and 2.5 mM acetyl-CoA as described in Section 2.4.
Fig. 4 shows that several acyl-CoAs were substrates for NAGS
and were converted into the corresponding N-acylglutamates.
N-butyrylglutamate and N-propionylglutamate were formed at approxi-
mately equal rates by NAGS, whereas the remaining branched-chain
acyl-CoAs only gave rise to limited amounts of glutamate esters. Trace
N-methylmalonylglutamate and no N-glutarylglutamate was detected.
Surprisingly, N-succinylglutamate was formed non-enzymatically
from succinyl-CoA and L-glutamate.
3.4. The presence of alternative N-acylglutamate conjugates in urine of
patients with short-chain related organic acidemias
The results described above prompted us to look for the presence
of alternative N-acylglutamate conjugates in urine of patients with activity
100
0.2 mM inhibitor
2.5mM Inhibitor
As (0.2 mMand 2.5 mM) on the NAGS activity was studied at an acetyl-CoA concentration
N-acylglutamate formation (µmol/min.mg)
0 5 10
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Fig. 4. The enzymatic production of N-acylglutamates from the corresponding acyl-CoA esters by NAGS. Puriﬁed NAGS was incubated with various acyl-CoA esters (0.2 mM) in the ab-
sence or presence of acetyl-CoA (0.2 mM, 2.5 mM). The N-acylglutamate formation were analysed on the UPLC–MS/MS and quantiﬁed with the use of N-acetyl-L-glutamic-2,3,3,4,4-d5
acid as internal standard. #: Formation of N-succinylglutamate by NAGS could not be determined, but nonenzymatic production of N-succinylglutamate was observed.
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amounts of N-isovalerylglutamate (112 ± 87 mmol/mol creatinine)
in the urine of 10 untreated IVA patients. The same was true for N-3-
methylcrotonylglutamate (5.6 ± 2.0 mmol/mol creatinine) which
was elevated in 3 patients with 3-methylcrotonyl-CoA carboxylase
deﬁciency consistent with previous reports [32–34]. We did not
detect N-3-methylcrotonylglutamate in patients with multiple
carboxylase deﬁciency. We also detected trace amounts of
urinary N-isovalerylglutamate (5.8 mmol/mol creatinine) and
N-isobutyrylglutamate (1.5 mmol/mol creatinine) in a patient with
the severe form of MADD. N-isobutyrylglutamate (0.5 mmol/mol
creatinine) was also identiﬁed in the urine of a patient with
presumed isobutyryl-CoA dehydrogenase deﬁciency (IBCDD). Urine
of control subjects did not reﬂect the presence of any of these gluta-
mate esters. N-isobutyrylglutamate has not reported before in liter-
ature. Importantly, the identity was conﬁrmed by GC–MS using a
chemically synthesized standard (Fig. 5).
Urinary N-propionylglutamate in patients with propionic
acidemia could not be detected in our series of patients. Surpris-
ingly N-butyrylglutamate was absent in urine of patients with
SCADD, ethylmalonic encephalopathy, or MADD. In addition,
N-methylmalonylglutamate and N-succinylglutamate were not
detected in urine of patients with methylmalonic acidemia and/or
succinyl-CoA ligase (SUCLA2 gene mutation) deﬁciency, respectively.4. Discussion
In this paper we have shown that the activity of puriﬁed human
N-acetylglutamate synthase is inhibited by a number of monocarbox-
ylic and dicarboxylic short-chain acyl-CoAs. Propionyl-CoA was found
to be a strong inhibitor among the tested CoA-esters, fully in line with
the life-threatening hyperammonemia which can be observed in the
neonatal form of propionic acidemia and methylmalonic acidemia
[25]. The ability of NAGS to convert propionyl-CoA to its glutamate
ester was quite considerable and is higher than reported before by
others [11,35,36]. However, N-propionylglutamate could not be
detected in the urines of 20 propionic acidemia patients.Butyryl-CoA inhibited NAGS to a slightly lesser degree, but was
equally effective as propionyl-CoA in its in vitro formation of gluta-
mate esters. However, we failed to identify N-butyrylglutamate in
the urines of 18 SCADD patients with a variety of homozygous and
compound heterozygous mutations. It is generally accepted that
patients who accumulate butyryl-CoA, i.e. those with SCAD-deﬁciency,
do not suffer from hyperammonemia, a ﬁnding which is seemingly in
contrast with our observations [18]. The moderate elevation of the
butyryl-CoA in SCADD, as exempliﬁed by the mild elevations of its
secondary metabolites ethylmalonic acid and butyrylcarnitine, most
probably contributes to the near-absence of hyperammonemia in this
condition. Isobutyryl-CoA, the structural isomer of butyryl-CoA derived
from the valine catabolic pathway, showed slightly less inhibition of
NAGS when compared with its straight-chain analogue. An accumula-
tion of isobutyryl-CoA has been shown to occur in patients with
MADD and (presumed) IBCDD (unpublished observations based on
the analysis of acylcarnitines and acylglycines). In line with these data
we identiﬁed N-isobutyrylglutamate in the urine of MADD as well as
IBCDD, which has not been reported in literature so far.
Isovaleryl-CoA inhibited the activity of NAGS in a similar way, as
compared to butyryl-CoA. Surprisingly, the in vitro formation of
N-isovalerylglutamate was rather low, in sharp contrast to the observa-
tions of a considerable accumulation of N-isovalerylglutamate in the
urines of IVA patients during episodes of metabolic decompensation.
It cannot be ruled out that the in vivo formed N-isovalerylglutamate is
quite resistant to degradation by aminoacylase(s) and consequently re-
mains elevated for some time. Earlier observations by Lindner et al. [37]
support this theory. They have shown that aminoacylase-1 favors
straight-chain acyl-moieties, whereas branched-chain N-acylamino
acids are poor substrates for the enzyme. These results explain our
ﬁndings of only branched-chain glutamate ester in urine of patient
with corresponding deﬁciencies whereas propionyl-glutamate and
butyryl-glutamate were not detected.
Dicarboxylic short-chain acyl-CoAs had limited effect on the ac-
tivity of NAGS, except at an acyl-CoA concentration of 2.5 mM
(Fig. 3). Trace N-methylmalonylglutamate and no enzymatic formation
of N-succinylglutamate and N-glutarylglutamate were observed. How-
ever succinyl-CoA and L-glutamate rapidly formed a glutamate ester
Fig. 5.Mass spectra of the di-TMS derivative of N-isobutyrylglutamic acid (A) The TMS derivative of trace amount of N-isobutyrylglutamate in the urine of a MADD patient, (B) The
TMS derivative of chemically synthesized N-isobutyrylglutamate.
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inhibition of NAGS by synthetic N-succinylglutamate and proved that
this was not the case (data not shown). Hyperammonemia has been
reported in a few isolated cases of severe succinyl-CoA ligase deﬁciency
with mutations in SUCLG1. The inhibitory effect of nonenzymatic
formed N-succinylglutamate on CPS1 may be the underlying mecha-
nism for the hyperammonemia and further investigation is needed to
conﬁrm this phenomenon observed in our in vitro study. An alternative
explanation may be the tertiary accumulation of propionyl-CoA in this
disorder, as the effect of the dicarboxylyl-CoAs is negligible. Although
severe hyperammonemia is associated with methylmalonic acidemia,
this is most likely due to the secondary accumulation of propionyl-
CoA in this disorder and to a lesser degree as a result of elevated
methylmalonyl-CoA as previously suggested in the literature [11].
Elevated blood ammonia levels have not been associated with GA1,
which concurs with our result of limited inhibition of NAGS activity by
glutaryl-CoA. No dicarboxylic N-acylglutamates were found in the
urine of patients with relevant organic acidemias.
The difference in the degree of severity of hyperammonemia among
the various organic acidemiasmay be attributed to the secondary in vivo
metabolic pathways and/or competing enzyme reactions resulting in
alleviation of the accumulation of toxic acyl-CoAs as well as formation
of alternative conjugates. Indeed, accumulating acyl-CoAs may enter
carboxylation, or thiolytic cleavage reactions and subsequently (ω-1)-
hydroxylation and ω-oxidation. Butyryl-CoA, isobutyryl-CoA and
isovaleryl-CoA possibly serve as substrates for neighboring mito-
chondrial short-chain dehydrogenases (SBCAD, IBCD or SCAD). The
cells also have the ability to conjugate these short-chain acyl-CoAs
to glycine, glucuronic acid, and L-carnitine which in all cases result
in (partially) detoxiﬁed substrates. The afﬁnities of the various
short-chain acyl-CoAs for these conjugating enzyme systems differ
considerably [38], thus one may expect organic acidemia patients toexcrete a variety of different conjugates in their urines. It can be fore-
seen that metabolomics analysis in this area will unravel the relative
importance of each conjugation system in every single patient,
thereby opening the way to personalized drug or food additive
treatment.
The availability of acetyl-CoA is another factor that should be taken
into account when interpreting the hyperammonemia associated with
organic acidemias. It is well known that patients with defects of the
mitochondrial fatty acid oxidation such as medium-chain acyl-CoA
dehydrogenase deﬁciency (MCADD) or very long-chain acyl-CoA dehy-
drogenase deﬁciency (VLCADD) may suffer from hyperammonemia.
This can be attributed to the inadequate production of acetyl-CoA
hampering the formation of NAG [39]. It can be learned from Fig. 4
that a high level of acetyl-CoA results in a less severe depression of
the NAGS activity using the same amount of short-chain acyl-CoA
and this is seemingly an advantage of the ketotic state. However, the
increased load of ammonia during catabolism to be handled by the
urea cycle probably makes the residual NAGS activity insufﬁcient.
Immediate treatment with N-carbamylglutamate, a non-physiological
activator of NAGS, which is available as the drug Carglumic acidR, as
well as reversal of the catabolic state is then indicated.
5. Conclusion
This study contributes to the understanding of hyperammonemia
in several organic acidemias. It can be concluded that both inhibition
of NAGS as well as formation of alternative N-acylglutamates has a
potential effect on the regulatory steps of urea production,
especially the activation of CPS. This awareness should prompt the
clinician to liberally apply the administration of stable glutamate
esters such as N-carbamylglutamate in all neonates with unexplained
hyperammonemia until a ﬁrm diagnosis has been established. The
2516 M. Dercksen et al. / Biochimica et Biophysica Acta 1842 (2014) 2510–2516successful application of N-carbamylglutamate in isovaleric academia
has recently been demonstrated [40]. Without doubt these studies
will eventually turn out to be useful in the design of personalized treat-
ment of patients with secondary hyperammonemia due to organic
acidemias, which are also strongly supported by J. Häberle et al. [41].
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.027.
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